E Fund Management Co. Ltd. Purchases New Holdings in Celcuity, Inc. $CELC

E Fund Management Co. Ltd. purchased a new position in shares of Celcuity, Inc. (NASDAQ:CELC) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 45,895 shares of the company’s stock, valued at approximately $4,802,000. E Fund Management Co. Ltd. owned 0.09% of Celcuity at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. NEA Management Company LLC increased its position in shares of Celcuity by 64.9% during the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock valued at $352,637,000 after purchasing an additional 1,391,300 shares during the last quarter. Avoro Capital Advisors LLC bought a new position in Celcuity during the fourth quarter valued at about $310,302,000. Soleus Capital Management L.P. increased its holdings in Celcuity by 17.0% during the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after buying an additional 437,696 shares during the last quarter. Vanguard Group Inc. increased its holdings in Celcuity by 10.7% during the fourth quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock worth $227,351,000 after buying an additional 220,386 shares during the last quarter. Finally, State Street Corp raised its position in Celcuity by 126.6% in the fourth quarter. State Street Corp now owns 1,637,687 shares of the company’s stock worth $163,343,000 after acquiring an additional 914,887 shares during the period. Institutional investors own 63.33% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Craig Hallum reissued a “buy” rating and set a $178.00 target price on shares of Celcuity in a research report on Wednesday, July 15th. Guggenheim upped their price objective on Celcuity from $165.00 to $175.00 and gave the company a “buy” rating in a research note on Monday. Stifel Nicolaus reduced their price objective on Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a report on Friday, August 14th. Leerink Partners set a $155.00 target price on Celcuity in a research report on Tuesday, June 2nd. Finally, Macquarie Infrastructure set a $160.00 target price on Celcuity in a research note on Thursday, May 28th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $154.55.

Celcuity Price Performance

Celcuity stock opened at $93.64 on Thursday. Celcuity, Inc. has a one year low of $44.42 and a one year high of $151.02. The business has a fifty day moving average price of $94.10 and a 200-day moving average price of $107.95. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. The firm has a market capitalization of $4.58 billion, a P/E ratio of -21.78 and a beta of 0.20.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). As a group, equities research analysts forecast that Celcuity, Inc. will post -4.51 EPS for the current year.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.